Details : TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CD...
Product Name : TS-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2022
Lead Product(s) : Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer
Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.
Product Name : Teysuno
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.
Product Name : Opdivo
Product Type : Antibody
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
